Abstract
e12562 Background: Since the first report by Mok T. et al. in 2008 showing clinical benefit of tyrosine kinase inhibitor for patients (pts) whose tumors harbor EGFR mutation, personalized medicine ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
